Some More Drugs That the Food and Drug Administration Approved

Nexavar (sorafenib tosylate) goes after the blood that's stocked for tumors. Then, the d-
rug goes to work and pulls the oxygen & nutrients from the tumors. So the tumors stop
growing. Nexavar put up some roadblocks in front of the vascular endothelial growth fa-
ctor (VEGF) and the platelet-derived growth factor (PDGF). It rightfully interrupts their p-
roceedings.

The therapy also closes the Raf-kinase passageways. When those actions occur, the
cancer cells can not go forward. The results from the phase three trial showed that the
participants who took Nexavar did not get other un-welcomed visits from the tumors.
So, the FDA saw the evidence and approved the the drug.

The inhibitor Sutent (sunitinib malate) worked effectively with Nexavar to punish tumors
severely. It focuses on the blood supply too & it shuts the PDGF and VEGF signaling
tunnels. The drug is strong enough to shrink tumors. After immunotherapy, some canc-
er patients have to battle some of the toughest tumors.

Some clinical trials were conducted and patients with metastasis kidney cancer replied
positively to the treatment. The Food and Drug Administration retrieved the results from
those studies and approved Suntent.

The medicine Torisel (temsirolimus) does mess with the mammalian target of rapamycy-
in (mTOR) kinase, so the cancer cells stop growing. The therapy puts an end to tumor m-
ultiplication and angiogenesis stimulation. So those harmful cells cease to exist.

The medication Afinitor (everolimus) also places a steel-like door in front of mammalian t-
arget of rapamycyin kinase, which is a standout protein. Afinitor also halts the cells from
growing and proliferating. It hinders angiogenesis & the metabolism of each cell, so the dr-
ug functions in plenty of good ways.

Voltrient (pazopanib) is another option that cancer patients have and it interrupts angiogen-
esis. It puts an end to the growth of the tumors' new blood vessels. Like Afinitor, it is mark-
eted to folks who have accelerated renal cell cancer. The treatment Inlyta (axitinib) should
be prescribed to patients who have accelerated renal cell carcinoma. The Food and Drug A-
dministration made sure to approve that one too.